A 70-year-old female patient with Parkinson’s disease has been taking carbidopa/levodopa for five years. Twelve months ago, her physician changed the dose to 8 orally disintegrating tablets (25/100 mg) per day and her symptoms were well-managed until recently. For the last a few weeks, the patient has been experiencing tremors in the hands and slowness in movement towards the end of the dosing interval. Identify the problem and suggest a pharmacotherapy management option for this patient.A 55-year-old male patient has mild dementia and mild hepatic impairment. The patient was recently diagnosed with Parkinson’s disease. Consider carbidopa/levodopa, tolcapone, and rasagiline to initiate treatment.Explain pharmacotherapy of migraine targeting the calcitonin gene-related peptide. Please answer at your own easy words. Answer should be to the point specific. I will rate you positive if you do so. Please don't use AI for answering this question.
A 70-year-old female patient with Parkinson’s disease has been taking carbidopa/levodopa for five years. Twelve months ago, her physician changed the dose to 8 orally disintegrating tablets (25/100 mg) per day and her symptoms were well-managed until recently. For the last a few weeks, the patient has been experiencing tremors in the hands and slowness in movement
towards the end of the dosing interval. Identify the problem and suggest a pharmacotherapy management option for this patient.
A 55-year-old male patient has mild dementia and mild hepatic impairment. The patient was recently diagnosed with Parkinson’s disease. Consider carbidopa/levodopa, tolcapone, and rasagiline to initiate treatment.
Explain pharmacotherapy of migraine targeting the calcitonin gene-related peptide.
Please answer at your own easy words. Answer should be to the point specific. I will rate you positive if you do so. Please don't use AI for answering this question.
Step by step
Solved in 2 steps
